CN115297890A - 用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物 - Google Patents

用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物 Download PDF

Info

Publication number
CN115297890A
CN115297890A CN202180012327.9A CN202180012327A CN115297890A CN 115297890 A CN115297890 A CN 115297890A CN 202180012327 A CN202180012327 A CN 202180012327A CN 115297890 A CN115297890 A CN 115297890A
Authority
CN
China
Prior art keywords
antibody
seq
light chain
variable region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180012327.9A
Other languages
English (en)
Chinese (zh)
Inventor
榎本笃
江﨑宽季
高桥雅英
宫井雄基
安藤良太
白木之浩
西田佳弘
松山诚
真锅史乃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Legal Person Foundation
National University Corp Donghai National University
Original Assignee
Medical Legal Person Foundation
National University Corp Donghai National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Legal Person Foundation, National University Corp Donghai National University filed Critical Medical Legal Person Foundation
Publication of CN115297890A publication Critical patent/CN115297890A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202180012327.9A 2020-02-03 2021-02-03 用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物 Pending CN115297890A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-016535 2020-02-03
JP2020016535 2020-02-03
PCT/JP2021/003851 WO2021157601A1 (ja) 2020-02-03 2021-02-03 がんを有する対象においてがんを処置することに用いるための抗ｍｅｆｌｉｎ抗体、および当該抗体を含む医薬組成物

Publications (1)

Publication Number Publication Date
CN115297890A true CN115297890A (zh) 2022-11-04

Family

ID=77200605

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180012327.9A Pending CN115297890A (zh) 2020-02-03 2021-02-03 用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物

Country Status (7)

Country Link
US (1) US20230084099A1 (https=)
EP (1) EP4101472A4 (https=)
JP (2) JPWO2021157601A1 (https=)
CN (1) CN115297890A (https=)
AU (1) AU2021217624A1 (https=)
CA (1) CA3168866A1 (https=)
WO (1) WO2021157601A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693682A (zh) * 2023-06-02 2023-09-05 涌源合生科技(深圳)有限公司 抗Tau蛋白抗体及其制备方法和用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
AU2021286655A1 (en) 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
KR20230109138A (ko) * 2020-10-16 2023-07-19 센티 바이오사이언시스, 인코포레이티드 키메라 수용체 및 이의 사용 방법
JP2025508050A (ja) * 2022-03-07 2025-03-21 ンカルタ・インコーポレイテッド Ｃｄ７０指向性がん免疫療法のための多重遺伝子編集細胞
JP2025030462A (ja) * 2023-08-23 2025-03-07 学校法人藤田学園 免疫担当細胞、治療剤、ｄｎａ、及びベクター

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151343A1 (en) * 2015-11-30 2017-06-01 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
US20170151344A1 (en) * 2015-11-30 2017-06-01 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
WO2019159825A1 (ja) * 2018-02-14 2019-08-22 国立大学法人名古屋大学 抗ｐｄ－１抗体／抗ｐｄ－ｌ１抗体療法の効果を予測するバイオマーカー

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017022472A1 (ja) 2015-08-03 2017-02-09 国立大学法人名古屋大学 未分化間葉系幹細胞マーカー及びその用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151343A1 (en) * 2015-11-30 2017-06-01 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
US20170151344A1 (en) * 2015-11-30 2017-06-01 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
WO2019159825A1 (ja) * 2018-02-14 2019-08-22 国立大学法人名古屋大学 抗ｐｄ－１抗体／抗ｐｄ－ｌ１抗体療法の効果を予測するバイオマーカー

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JAMES W. PURCELL 等: "LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates", CANCER RESEARCH, vol. 78, no. 14, 15 July 2018 (2018-07-15), pages 1 - 32, XP055745280, DOI: 10.1158/0008-5472.CAN-18-0327 *
KEIKO MAEDA 等: "Identification of Meflin as a Potential Marker for Mesenchymal Stromal Cells", SCIENTIFIC REPORTS, vol. 6, no. 1, 29 February 2016 (2016-02-29), pages 1 - 15 *
YASUYUKI MIZUTANI1 等: "Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis", CANCER RESEARCH, vol. 79, no. 20, 22 August 2019 (2019-08-22), pages 1 - 43 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693682A (zh) * 2023-06-02 2023-09-05 涌源合生科技(深圳)有限公司 抗Tau蛋白抗体及其制备方法和用途
CN116693682B (zh) * 2023-06-02 2024-04-19 涌源合生科技(深圳)有限公司 抗Tau蛋白抗体及其制备方法和用途

Also Published As

Publication number Publication date
JPWO2021157601A1 (https=) 2021-08-12
WO2021157601A1 (ja) 2021-08-12
AU2021217624A1 (en) 2022-09-01
JP2026048884A (ja) 2026-03-17
US20230084099A1 (en) 2023-03-16
EP4101472A1 (en) 2022-12-14
CA3168866A1 (en) 2021-08-12
EP4101472A4 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
CN115297890A (zh) 用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物
US10640571B2 (en) Human monoclonal antibodies specific for glypican-3 and use thereof
CA2919359C (en) Anti-her2 antibody and conjugate thereof
JP7592320B2 (ja) ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物
JP6006640B2 (ja) 高い内在化能力を有する抗ｃｄｈ３抗体
US9441048B2 (en) Antibody for 3′-isoLM1 and 3′,6′-iso-LD1 gangliosides
WO2017196847A1 (en) Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
CN104520331A (zh) 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
CN106467574B (zh) 靶向于组织因子的抗体、其制备方法和用途
WO2014126198A1 (ja) 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用
CN110582514B (zh) 纤溶酶可切割的抗不溶性纤维蛋白的抗体与药物的偶联物
JP7531224B2 (ja) ポドカリキシン及びｔｒａ関連抗体、調製方法、並びに抗癌治療剤としての使用
CN113728010A (zh) 特异性结合到水通道蛋白3(aqp3)的细胞外域的抗aqp3单克隆抗体及其用途
CN111201244A (zh) 特异性结合到水通道蛋白3(aqp3)的细胞外域的抗aqp3单克隆抗体及其用途
CN121285575A (zh) 抗体及其抗体药物偶联物
CN121986119A (en) Humanized MUC1 antibodies and antibody drug conjugates
CN121824756A (zh) 一种cldn3单克隆抗体及其应用
JP2025183289A (ja) 抗ｃｄ２２８抗体およびその薬物コンジュゲート
CN120189525A (zh) 靶向b7-h3和trop2的抗体-药物偶联物及其用途
WO2025125557A1 (en) Composition comprising an antibody which binds to human igf2bp1 present on the cell surface of a target cell
CN121824757A (zh) 一种能够结合催乳素受体prlr的抗体及其用途
WO2023190465A1 (ja) 抗ヒトｓｅｍａ７ａ抗体
CN121824758A (zh) 一种具有人猴交叉反应性的prlr单克隆抗体及其用途
CN121673408A (zh) 一种特异性结合prlr的小鼠单克隆抗体及其应用
CN121627886A (zh) 一种特异性结合催乳素受体prlr的小鼠单克隆抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination